🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million instances each year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, alternatively called Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

According to findings detailed in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research involved hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians directly involved have voiced hope. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.